Authorized purpose: Morph automatically labels, visualizes, and volumetrically quantifies segmentable brain structures from MR images and may compare measurements with reference percentile data; it is adjunctive and not the sole basis for final decisions.
Clinical role
Automatic brain-structure labeling, visualization, volumetric quantification, and reference comparison.
Images and patients
MRI · Brain
Key limitation
Keep in mind: Morph is adjunctive and not the sole basis for clinical decisions. Results depend on standardized T1 acquisition, segmentable structures, reference data, and professional review.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Morph automatically labels, visualizes, and volumetrically quantifies segmentable brain structures from MR images and may compare measurements with reference percentile data; it is adjunctive and not the sole basis for final decisions.
Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Brain Input: Standardized DICOM T1 brain MR images.
Who uses it?Intended users: Radiologists, neurologists, neuroradiologists, and other trained medical professionals.
What does the software produce?Output: Quantitative brain-structure assessments, reference comparisons, reports, and visualizations for clinician review.
What is its most important limitation?Key limitation: Morph is adjunctive and not the sole basis for clinical decisions. Results depend on standardized T1 acquisition, segmentable structures, reference data, and professional review.
Clinical takeaway. Clinical role: Morph automatically labels, visualizes, and volumetrically quantifies segmentable brain structures from MR images and may compare measurements with reference percentile data; it is adjunctive and not the sole basis for final decisions.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports standalone segmentation testing on 64 independent 3D T1-weighted MRI scans, with a reference standard of manual segmentation by two U.S. board-certified neuroradiologists. Against a predefined mean DSC acceptance criterion of 0.70, Dice coefficients were >0.97 in the lateral ventricles and approximately 0.71 in occipital CSF regions, and the overall mean DSC exceeded 0.85. Volumetric agreement with expert reference measurements was within predefined clinically acceptable 95% LoA ranges. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Morph automatically labels, visualizes, and volumetrically quantifies segmentable brain structures from MR images and may compare measurements with reference percentile data; it is adjunctive and not the sole basis for final decisions.
Morph is adjunctive and not the sole basis for clinical decisions. Results depend on standardized T1 acquisition, segmentable structures, reference data, and professional review.
The exact FDA document reports standalone segmentation testing on 64 independent 3D T1-weighted MRI scans, with a reference standard of manual segmentation by two U.S. board-certified neuroradiologists. Against a predefined mean DSC acceptance criterion of 0.70, Dice coefficients were >0.97 in the lateral ventricles and approximately 0.71 in occipital CSF regions, and the overall mean DSC exceeded 0.85. Volumetric agreement with expert reference measurements was within predefined clinically acceptable 95% LoA ranges. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Standalone performance testing was conducted using a validation dataset consisting of 64 independent 3D T1-weighted MRI scans." … "The reference standard for segmentation accuracy evaluation was established through manual segmentation of 64 MRI scans by two U.S. board-certified neuroradiologists". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports standalone segmentation testing on 64 independent 3D T1-weighted MRI scans, with a reference standard of manual segmentation by two U.S. board-certified neuroradiologists. Against a predefined mean DSC acceptance criterion of 0.70, Dice coefficients were >0.97 in the lateral ventricles and approximately 0.71 in occipital CSF regions, and the overall mean DSC exceeded 0.85. Volumetric agreement with expert reference measurements was within predefined clinically acceptable 95% LoA ranges. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Standalone performance testing was conducted using a validation dataset consisting of 64 independent 3D T1-weighted MRI scans." … "The reference standard for segmentation accuracy evaluation was established through manual segmentation of 64 MRI scans by two U.S. board-certified neuroradiologists". Read from the exact FDA decision document on 2026-11-14.
No single product-level sensitivity value was promoted because the reviewed FDA material is workflow, module, sequence, or population specific.
Reported specificity
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No single product-level specificity value was promoted because the reviewed FDA material is workflow, module, sequence, or population specific.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K260032 FDA evidence package for Morph
DesignFDA 510(k) verification and validation evidence described in the exact submission
PopulationBrain
Scopeexact submission
Tested versionMorph
IndependenceSponsor or vendor study
K260032
Manufacturer evidence submitted for the exact FDA decision. It is not independent clinical validation, and local technical, clinical, privacy, security, and workflow acceptance remains necessary.
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging or clinical service line and verify payer, site-of-service, coding, and coverage assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Source context, not route validation: The FDA package describes standardized DICOM T1 input and web-client results; exact PACS routing, report return, and local interfaces require testing.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The FDA package describes a web client with either cloud AWS or on-premises server deployment; the installed mode, hosting contract, security boundary, and local qualification remain unverified.
Scope: Exact FDA submission.
Confirm processing location, queue ownership, exclusions and exact AI build.
Unresolved route: Quantitative brain-structure assessments, reference comparisons, reports, and visualizations for clinician review.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The FDA package describes a web client with either cloud AWS or on-premises server deployment; the installed mode, hosting contract, security boundary, and local qualification remain unverified.
Only radiologists, neurologists, neuroradiologists, and other trained medical professionals. should operate or interpret this product. Local onboarding must cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Monitor K260032 by exact software, hardware, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Morph is adjunctive and not the sole basis for clinical decisions. Results depend on standardized T1 acquisition, segmentable structures, reference data, and professional review.
The FDA package describes a web client with either cloud AWS or on-premises server deployment; the installed mode, hosting contract, security boundary, and local qualification remain unverified.
exact submission · checked 2026-09-04
FDA-described deployment details do not establish current hosting contracts, security controls, uptime, or local qualification.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Morph is adjunctive and not the sole basis for clinical decisions. Results depend on standardized T1 acquisition, segmentable structures, reference data, and professional review.
exact submission · checked 2026-09-04
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-04
No exact-product price or product-specific reimbursement was established in the reviewed public material.
Monitor K260032 by exact software, hardware, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Morph is adjunctive and not the sole basis for clinical decisions. Results depend on standardized T1 acquisition, segmentable structures, reference data, and professional review.
exact submission · checked 2026-09-04
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-04Last searched
25Fields reviewed
11Source classes checked
20Screened PubMed leads
10Screened trial leads
0Unreviewed FDA recall leads
Screened 20 PubMed titles and 10 trial records. They are unrelated lexical matches for morph or clinical procedures and do not identify BeauBrain Morph or K260032; all 30 are quarantined. The current discovery snapshot contains 20 PubMed and 10 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, acr ai central product, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, fda decision summary, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public list price for the exact cleared product version was established. Obtain a written quote separating license, implementation, interfaces, compute, storage, training, support, upgrades, renewal, and exit costs.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not publicly available - checked 2026-09-04 - Exact FDA submission
The FDA decision material does not establish the complete security posture for the exact product and deployment. Obtain architecture, identity, audit, encryption, retention, support-access, vulnerability-management, and incident-response evidence.
Authorized purpose: ANDI 2.2 processes brain MR images for atlas-assisted visualization, segmentation and volumetric quantification, presenting adjunctive DICOM-readable information for trained medical professionals; it does not predict, diagnose or interpret brain health.
Authorized purpose: Brain MRI morphometry and white matter hyperintensity quantification, including normative comparison and longitudinal change assessment for clinician review.
Authorized purpose: Adjunctive quantitative brain MRI analysis that compares patient measures with normative and longitudinal references; a physician reviews all results and makes the clinical decision.
Authorized purpose: Adjunctive brain MRI morphometry and lesion-quantification support for qualified healthcare professionals, including segmented overlays, volumetric measurements, normative percentiles and longitudinal comparison.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.